BMS Celgene Charter Oak Partner

Connecticut Oncology Association

Home

About Us

Officers

Contact Us

Events

Corporate Partners

Membership

Member Application

Resources

Members Only

Corporate Sites

https://www.bms.com/

https://www.celgene.com/

Healthcare Providers Site

Patients and Caregivers Site

Contact in CT:

Rich Boyle

570-241-2441

Richard.Boyle@bms.com

Important News and Information

2026 Patient Advocacy Resources

Understanding CELMoDs (Cereblon E3 Ligase Modulatory Drugs)

BMS-activated treatment centers are expanding, providing the potential benefits of Breyanzi® to more patients

06/26/2025 U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels

04/11/2025 U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

04/08/20025 U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer

COVID-19 Our Response and Path Forward - 05/13/2020

Connecticut Oncology Association (CtOA)

c/o Dawn Holcombe

33 Woodmar Circle
South Windsor, CT 06074
(860) 305-4510

Website design by Sister Webs Design Studio, where 5% of profits are donated to women's cancer funds

Powered by Wild Apricot Membership Software